Eclipse Axcis PTMR Clinical Data Could Bring Approval In September
This article was originally published in The Gray Sheet
Executive Summary
Eclipse Surgical expects the PMA for its Axcis percutaneous transmyocardial revascularization (PTMR) device to receive less resistance from FDA's Circulatory System Devices Advisory Panel than was encountered in the review of the company's TMR product in 1998.You may also be interested in...
Postmarket Surveillance Orders Expected To Follow Final Rule
BELIEF Data May Dispel "Placebo Effect" Shadow Over Eclipse PTMR
Eclipse's PACIFIC Trial Suggests Improved Outcomes For PTMR Patients
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: